Logo image of MENS

JYONG BIOTECH LTD (MENS) Stock Fundamental Analysis

USA - NASDAQ:MENS - KYG831161065 - Common Stock

38.19 USD
-0.05 (-0.13%)
Last: 11/14/2025, 8:01:21 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MENS. MENS was compared to 533 industry peers in the Biotechnology industry. MENS may be in some trouble as it scores bad on both profitability and health. MENS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MENS has reported negative net income.
MENS had a negative operating cash flow in the past year.
MENS Yearly Net Income VS EBIT VS OCF VS FCFMENS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -2M -4M -6M

1.2 Ratios

MENS has a Return On Assets of -47.42%. This is comparable to the rest of the industry: MENS outperforms 52.17% of its industry peers.
Industry RankSector Rank
ROA -47.42%
ROE N/A
ROIC N/A
ROA(3y)-58.86%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MENS Yearly ROA, ROE, ROICMENS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 20 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MENS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MENS Yearly Profit, Operating, Gross MarginsMENS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for MENS remains at a similar level compared to 1 year ago.
MENS has a worse debt/assets ratio than last year.
MENS Yearly Shares OutstandingMENS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 20M 40M 60M
MENS Yearly Total Debt VS Total AssetsMENS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 5M 10M 15M

2.2 Solvency

An Altman-Z score of 30.04 indicates that MENS is not in any danger for bankruptcy at the moment.
The Altman-Z score of MENS (30.04) is better than 93.79% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 30.04
ROIC/WACCN/A
WACCN/A
MENS Yearly LT Debt VS Equity VS FCFMENS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 10M -10M -20M -30M

2.3 Liquidity

MENS has a Current Ratio of 0.02. This is a bad value and indicates that MENS is not financially healthy enough and could expect problems in meeting its short term obligations.
MENS's Current ratio of 0.02 is on the low side compared to the rest of the industry. MENS is outperformed by 98.31% of its industry peers.
MENS has a Quick Ratio of 0.02. This is a bad value and indicates that MENS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of MENS (0.02) is worse than 98.31% of its industry peers.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
MENS Yearly Current Assets VS Current LiabilitesMENS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 5M 10M

More info and screens

0

3. Growth

3.1 Past

MENS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.43%, which is quite impressive.
EPS 1Y (TTM)31.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MENS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MENS Price Earnings VS Forward Price EarningsMENS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MENS Per share dataMENS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

MENS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JYONG BIOTECH LTD

NASDAQ:MENS (11/14/2025, 8:01:21 PM)

38.19

-0.05 (-0.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.14%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap2.90B
Revenue(TTM)N/A
Net Income(TTM)-3.02M
AnalystsN/A
Price TargetN/A
Short Float %0.49%
Short Ratio0.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS-0.48
TBVpS-0.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -47.42%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.86%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z 30.04
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.43%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-39.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-39.33%
OCF growth 3YN/A
OCF growth 5YN/A

JYONG BIOTECH LTD / MENS FAQ

What is the fundamental rating for MENS stock?

ChartMill assigns a fundamental rating of 1 / 10 to MENS.


What is the valuation status of JYONG BIOTECH LTD (MENS) stock?

ChartMill assigns a valuation rating of 0 / 10 to JYONG BIOTECH LTD (MENS). This can be considered as Overvalued.


How profitable is JYONG BIOTECH LTD (MENS) stock?

JYONG BIOTECH LTD (MENS) has a profitability rating of 0 / 10.